On February 10, 2016, Naeja Pharmaceutical Inc. (“Naeja” or the "Company") filed a Notice of Intention to Make a Proposal under the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3, as amended, wherein MNP Ltd. was appointed as Licensed Insolvency Trustee. The Creditors approved the proposal however the Court did not approve the proposal and on May 13, 2016 the Company was declared bankrupt.
On May 13, 2016, Deloitte Restructuring Inc. (“Deloitte” and the “Receiver”) was appointed Receiver and Manager by an order (the “Receivership Order”) of the Court of Queen’s Bench of Alberta (the “Court”) over all current and future assets, undertakings and properties of every nature and kind whatsoever, and wherever situate, including all proceeds thereof (the “Property”) of Naeja by way of an application brought forward by Mrs. Celine Micetich (the “Director” and “Secured Creditor”).
On May 30, 2016, at the First Meeting of Creditors in the bankruptcy of Naeja, Deloitte substituted MNP Ltd. as Licensed Insolvency Trustee of the Company (the “Trustee”).
Deloitte Restructuring Inc. was discharged as Receiver on April 25, 2024.
For further information, please contact:
Christopher Knox1500 Manulife Place10180-101 StreetEdmonton, AB T5J 4K1Direct: 780-401-3913Fax: 780-421-3782Email: cknox@deloitte.ca
Last updated Apr 25, 2024
